Niagen Bioscience, Inc. NAGE

What this company does

Niagen Bioscience, Inc. commercializes food-grade Niagen, a proprietary form of nicotinamide riboside chloride, as a dietary and food ingredient, and sells Tru Niagen, a finished dietary supplement featuring Niagen, directly to consumers. For the years ended December 31, 2025 and 2024, its net sales were approximately $129.4 million and $99.6 million, respectively. As of December 31, 2025, Niagen Bioscience had 117 full-time employees, none of whom were represented by a labor union. Its net sales are reported across a Consumer Products segment, an Ingredients segment and an Analytical Reference Standards and Services segment, while its pharmaceutical segment did not generate net sales during the periods presented. It supplies pharmaceutical-grade Niagen to U.S. FDA-registered 503B outsourcing facilities, in addition to compound pharmacies abroad, which compound and distribute Niagen intravenous and injectable Niagen formulations for use with a prescription. Its pharmaceutical segment is pursuing pharmaceutical development of NAD+ precursors for potential therapeutic applications in advanced aging rare diseases, and to date its activities have been limited to research and development, including preclinical and clinical studies and regulatory planning activities. Effective March 19, 2025, the company changed its name to "Niagen Bioscience, Inc."

Written from the business description in Niagen Bioscience, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.